Zenas BioPharma, Inc. $ZBIO Stock Position Lowered by Eversept Partners LP

Eversept Partners LP lessened its position in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 23.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 121,016 shares of the company’s stock after selling 37,726 shares during the quarter. Eversept Partners LP’s holdings in Zenas BioPharma were worth $4,394,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Zenas BioPharma in the 4th quarter valued at approximately $38,000. Quarry LP lifted its position in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Zenas BioPharma in the 3rd quarter valued at approximately $30,000. CWM LLC lifted its position in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zenas BioPharma in the 4th quarter valued at approximately $95,000.

Zenas BioPharma Stock Up 2.1%

Zenas BioPharma stock opened at $18.58 on Thursday. The firm has a market cap of $1.17 billion, a PE ratio of -2.19 and a beta of -0.71. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The firm’s 50 day moving average price is $19.25 and its two-hundred day moving average price is $24.12. Zenas BioPharma, Inc. has a twelve month low of $8.91 and a twelve month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter last year, the business posted ($0.80) EPS. On average, research analysts predict that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZBIO shares. Guggenheim upped their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Friday, March 27th. Morgan Stanley upped their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.29.

Insider Transactions at Zenas BioPharma

In other Zenas BioPharma news, Director Hongbo Lu purchased 3,768 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the purchase, the director directly owned 426,736 shares in the company, valued at $7,950,091.68. This trade represents a 0.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were acquired at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the director owned 2,359,025 shares in the company, valued at $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 273,768 shares of company stock worth $5,150,198 in the last 90 days. 22.00% of the stock is owned by insiders.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.